# Memo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/memo-therapeutics

- Industry: Biotechnology
- Headquarters: Schlieren, Switzerland
- Website: www.memo-therapeutics.com
- Total disclosed funding: $98M
- Latest round: Series C (May 7, 2024)
- Investors on record: 16

## About

Founded in 2012 by Christoph Esslinger, and based in Schlieren, Switzerland, Memo Therapeutics AG is a late-stage biotechnology company that operates as a developer of recombinant immunoglobulins and human-derived monoclonal antibodies for antibody and vaccine development. In May 2024, Memo Therapeutics AG raised CHF 20 million in Series C funding from Ysios Capital Partners and Kurma Partners, with participation from BB Pureos Bioventures, Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group Holding, Fresenius Medical Care Ventures and Redalpine.

The firm's product AntiBKV, targets BK virus infections in kidney transplant patients. The firm also offers additional antibodies for cytomegalovirus and immuno-oncology targets, with a partnership with Ono Pharmaceutical. The company utilizes its proprietary DROPZYLLA® technology for antibody screening, leveraging immortal cell libraries and nanodroplet technology to identify and isolate effective antibodies.

The company intends to use the May 2024 funding to further develop its antibody, AntiBKV.

## Funding rounds

- Series C, May 7, 2024, $22M — Schroders Capital, Ysios Capital Partners, Vesalius Biocapital, Kurma Partners, Redalpine, Fresenius Medical Care Ventures, Adjuvant Capital, Swisscanto, Pureos Bioventures, Verve Ventures, GF Group Holding
- Series C, Nov 2, 2023, $28M — Schroders Capital, Vesalius Biocapital, Redalpine, Fresenius Medical Care Ventures, Swisscanto, Pureos Bioventures, Verve Ventures, GF Group Holding
- Series B, Dec 1, 2021, $25M — Zürcher Kantonalbank, Vesalius Biocapital, Fresenius Medical Care Ventures, Adjuvant Capital, Swisscanto, Verve Ventures, GF Group Holding
- Series B, Nov 6, 2020, $15M — Schroders Capital, investiere, Redalpine, Swisscanto, Bernina BioInvest AG, Jaquet Partners AG
- Series A, May 9, 2018, $5M — Schroders Capital, Zürcher Kantonalbank, Redalpine
- Series A, Jul 23, 2015, $2.4M — Zürcher Kantonalbank, EVA, Redalpine

## Investors

- Zürcher Kantonalbank — Series A, Series B
- EVA (https://capitalatlas.ai/funds/eva) — Series A
- Redalpine (https://capitalatlas.ai/funds/redalpine) — Series A, Series B, Series C
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series A, Series B, Series C
- investiere — Series B
- Swisscanto (https://capitalatlas.ai/funds/swisscanto) — Series B, Series C
- Bernina BioInvest AG — Series B
- Jaquet Partners AG — Series B
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series B, Series C
- Fresenius Medical Care Ventures (https://capitalatlas.ai/funds/fresenius-medical-care-ventures) — Series B, Series C
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series B, Series C
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series B, Series C
- GF Group Holding (https://capitalatlas.ai/funds/gf-group-holding) — Series B, Series C
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series C
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series C
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series C